Kintara Therapeutics, a biopharmaceutical company specializing in the development of treatments for solid tumor cancers, will be participating in the fifth annual Glioblastoma Awareness Day in Washington, D.C. This event aims to raise awareness and support for research advancements in glioblastoma (GBM). Kintara's leading treatment candidate for GBM, VAL-083, is currently being evaluated in the GBM AGILE clinical trial.
The GBM AGILE trial is a Phase 2/3 clinical trial conducted by the Global Coalition for Adaptive Research. It is an international study designed to quickly identify effective therapies for patients with glioblastoma. The unique aspect of this trial is that it allows multiple therapies from different pharmaceutical partners to be evaluated simultaneously.
Kintara Therapeutics is committed to developing innovative cancer treatments to address unmet medical needs. Their late-stage pipeline includes two promising therapeutics: VAL-083 for glioblastoma and REM-001 Therapy for cutaneous metastatic breast cancer. VAL-083 has demonstrated clinical activity against various types of cancer and is currently being advanced through the GB